Often treated as a technical regulatory exercise, EUDAMED carries significant contractual and governance risks for pharmaceutical companies. Insights from Martin King highlight common role-allocation mistakes and the contract fixes in-house counsel should prioritise before May 2026.
Filed under
Topics
Organisations
Laws
Industries
